Comparison of 4 Screening Methods for Detecting Fluoropyrimidine Toxicity Risk: Identification of the Most Effective, Cost-Efficient Method to Save Lives
Background: Fluoropyrimidines (FPs) carry around 20% risk of G3-5 toxicity and 0.2-1% risk of death, due to dihydropyrimidine dehydrogenase (DPD) deficiency. Several screening approaches exist for predicting toxicity, however there is ongoing debate over which method is best. This study compares 4 s...
Main Authors: | Olivier Capitain, Valérie Seegers, Jean-Philippe Metges, Roger Faroux, Claire Stampfli, Marc Ferec, Tamara Matysiak Budnik, Hélène Senellart, Valérie Rossi, Nadège Blouin, Jonathan Dauvé, Mario Campone |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-09-01
|
Series: | Dose-Response |
Online Access: | https://doi.org/10.1177/1559325820951367 |
Similar Items
-
PHARMACOKINETIC STUDIES OF BETA-BLOCKERS AND FLUOROPYRIMIDINES.
by: SCHAAF, LARRY JOE.
Published: (1985) -
DPD status and fluoropyrimidines-based treatment: high activity matters too
by: Emmanuel Chamorey, et al.
Published: (2020-05-01) -
Overexpression of p67phox in Response to Fluoropyrimidines in HCT116 Cells
by: Ufuk Ozer, et al.
Published: (2016-12-01) -
Folinic Acid Enhanced Cytotoxicity of Fluoropyrimidines In Human Breast Cancer Cells
by: Mandelbaum-Shavit Frederika
Published: (1993-02-01) -
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01)